KR102037502B1 - 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 - Google Patents

고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 Download PDF

Info

Publication number
KR102037502B1
KR102037502B1 KR1020177019929A KR20177019929A KR102037502B1 KR 102037502 B1 KR102037502 B1 KR 102037502B1 KR 1020177019929 A KR1020177019929 A KR 1020177019929A KR 20177019929 A KR20177019929 A KR 20177019929A KR 102037502 B1 KR102037502 B1 KR 102037502B1
Authority
KR
South Korea
Prior art keywords
compound
certain embodiments
cancer
shows
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177019929A
Other languages
English (en)
Korean (ko)
Other versions
KR20170095374A (ko
Inventor
롱리앙 첸
토모노리 이치바카세
춘롱 마
크리스토퍼 매튜스
하지메 모토요시
콜린 오브라이언
켄타로 야지
나오키 요시카와
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102037502(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20170095374A publication Critical patent/KR20170095374A/ko
Application granted granted Critical
Publication of KR102037502B1 publication Critical patent/KR102037502B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020177019929A 2014-12-18 2015-12-17 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 Active KR102037502B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US62/093,564 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US62/115,223 2015-02-12
US201562180222P 2015-06-16 2015-06-16
US62/180,222 2015-06-16
PCT/IB2015/002489 WO2016097862A2 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Publications (2)

Publication Number Publication Date
KR20170095374A KR20170095374A (ko) 2017-08-22
KR102037502B1 true KR102037502B1 (ko) 2019-10-28

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019929A Active KR102037502B1 (ko) 2014-12-18 2015-12-17 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논

Country Status (29)

Country Link
US (3) US10676473B2 (enExample)
EP (2) EP3677582B1 (enExample)
JP (3) JP6778195B2 (enExample)
KR (1) KR102037502B1 (enExample)
CN (1) CN107108609B (enExample)
AU (1) AU2015365580B2 (enExample)
BR (1) BR112017013149B1 (enExample)
CA (1) CA2970864C (enExample)
CL (1) CL2017001561A1 (enExample)
CO (1) CO2017005910A2 (enExample)
CR (1) CR20170249A (enExample)
DK (1) DK3233857T3 (enExample)
DO (1) DOP2017000130A (enExample)
EA (1) EA032291B1 (enExample)
EC (1) ECSP17038100A (enExample)
ES (1) ES2788454T3 (enExample)
GE (1) GEP20197050B (enExample)
IL (1) IL252941B (enExample)
MX (1) MX373586B (enExample)
MY (1) MY199935A (enExample)
NZ (1) NZ732371A (enExample)
PE (1) PE20171179A1 (enExample)
PH (1) PH12017501123A1 (enExample)
PL (1) PL3233857T3 (enExample)
SG (1) SG11201701911QA (enExample)
TN (1) TN2017000080A1 (enExample)
UA (1) UA120632C2 (enExample)
WO (1) WO2016097862A2 (enExample)
ZA (1) ZA201701800B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3677582B1 (en) * 2014-12-18 2023-01-25 Calithera Biosciences Inc. Solid state forms of fused heteroaromatic pyrrolidinones
WO2018013239A1 (en) * 2016-07-13 2018-01-18 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
KR20200073216A (ko) 2017-10-19 2020-06-23 바이엘 애니멀 헬스 게엠베하 동물에서의 질환의 치료 및 방지를 위한 융합된 헤테로방향족 피롤리돈의 용도
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
ES2971892T3 (es) * 2018-12-14 2024-06-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd Formas cristalinas del inhibidor de Syk sal hidrocloruro de 5-fluoro-1-metil-3-[[5-[4-(3-oxetanil)-1-piperazinil]-2-piridinil]amino]-6-(1H-pirazol-3-il)-2(1H)-quinolinona (1:1)
JP2022519383A (ja) 2019-02-07 2022-03-23 ヤンセン バイオテツク，インコーポレーテツド ジヒドロオロト酸デヒドロゲナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
JP2022552496A (ja) 2019-10-10 2022-12-16 ヤンセン バイオテツク，インコーポレーテツド ビアリールジヒドロオロト酸デヒドロゲナーゼ阻害剤
IL293965A (en) 2019-12-19 2022-08-01 Janssen Pharmaceutica Nv History of Spiro straight chain transformed
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
JP2024518497A (ja) 2021-05-11 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 併用療法
JP2025540762A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ
WO2024114664A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
PL2516434T3 (pl) 2009-12-23 2015-11-30 Takeda Pharmaceuticals Co Skondensowane heteroaromatyczne pirolidynony jako inhibitory SYK
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
EP3677582B1 (en) * 2014-12-18 2023-01-25 Calithera Biosciences Inc. Solid state forms of fused heteroaromatic pyrrolidinones

Also Published As

Publication number Publication date
CN107108609B (zh) 2020-02-18
CN107108609A (zh) 2017-08-29
MX2017007162A (es) 2017-08-28
ZA201701800B (en) 2020-05-27
WO2016097862A3 (en) 2016-08-11
PL3233857T3 (pl) 2020-07-27
DK3233857T3 (da) 2020-04-27
US11352355B2 (en) 2022-06-07
BR112017013149A2 (pt) 2018-04-10
AU2015365580B2 (en) 2020-04-02
MX373586B (es) 2020-05-05
US20230348461A1 (en) 2023-11-02
EP3677582B1 (en) 2023-01-25
CR20170249A (es) 2017-09-25
GEP20197050B (en) 2019-12-10
US20160176869A1 (en) 2016-06-23
PH12017501123A1 (en) 2017-11-27
JP2020143081A (ja) 2020-09-10
PE20171179A1 (es) 2017-08-22
SG11201701911QA (en) 2017-04-27
MY199935A (en) 2023-11-29
CL2017001561A1 (es) 2018-01-12
EP3233857B1 (en) 2020-03-11
KR20170095374A (ko) 2017-08-22
WO2016097862A2 (en) 2016-06-23
DOP2017000130A (es) 2017-07-15
EA201791369A1 (ru) 2017-10-31
IL252941B (en) 2020-11-30
US20200339573A1 (en) 2020-10-29
EP3677582A1 (en) 2020-07-08
IL252941A0 (en) 2017-08-31
HK1243406A1 (zh) 2018-07-13
EP3233857A2 (en) 2017-10-25
UA120632C2 (uk) 2020-01-10
BR112017013149B1 (pt) 2022-10-11
ES2788454T3 (es) 2020-10-21
CA2970864C (en) 2020-04-14
CO2017005910A2 (es) 2017-10-20
ECSP17038100A (es) 2017-12-01
NZ732371A (en) 2023-04-28
JP2017537969A (ja) 2017-12-21
US10676473B2 (en) 2020-06-09
TN2017000080A1 (en) 2018-07-04
JP6778195B2 (ja) 2020-10-28
AU2015365580A1 (en) 2017-07-06
JP2022017477A (ja) 2022-01-25
JP6974534B2 (ja) 2021-12-01
EA032291B1 (ru) 2019-05-31
CA2970864A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
KR102037502B1 (ko) 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논
ES2704525T3 (es) Derivados de naftiridina como antagonistas de integrina AlfaVBeta6 para el tratamiento de, por ejemplo, enfermedades fibróticas
KR20220101664A (ko) Pd-1/pd-l1 억제제의 염 및 결정질 형태
IL267532A (en) Preparations and methods for inhibiting arginase activity
HK1204623A1 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
CA2849340A1 (en) Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
CA2995909A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
WO2015110092A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
CN110896636B (zh) 抑制mps1激酶的化合物的盐、其制备以及包含它的制剂
HK40033008B (en) Solid state forms of fused heteroaromatic pyrrolidinones
HK40033008A (en) Solid state forms of fused heteroaromatic pyrrolidinones
JP2024514532A (ja) 大環状アゾロピリジン
AU2017304103A1 (en) Cyclic peptides as C5 a receptor antagonists
HK1243406B (zh) 稠合杂芳族吡咯烷酮的固态形式
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40000399A (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
HK40004704A (en) Cyclic peptides as c5 a receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000